Inflammatory Bowel Disease Market Size 2024-2028: Industry Growth and Insights

The inflammatory bowel disease (IBD) market is poised for significant growth, with a forecasted increase of USD 7.62 billion at a CAGR of 5.48% between 2023 and 2028. The rise in the incidence of IBD worldwide is driving the demand for effective therapeutics. Recent advancements, such as Lilly's Mirikizumab, an oral JAK inhibitor, are transforming the treatment landscape. However, challenges such as the high cost of IBD therapeutics and reimbursement regulations are affecting the market.

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Distribution Channel:
- Offline
- Online
By Type:
- Crohn’s Disease
- Ulcerative Colitis

Regional Market

North America (37% Market Contribution)
- United States: Over 2.6 million diagnosed cases as of 2022, driving demand for advanced therapies.
- Canada: Projected IBD cases to reach 470,000 by 2035, increasing focus on R&D.
Europe
- United Kingdom: High adoption of biologic drugs like Entyvio and Cimzia due to national healthcare system coverage.
Asia
- China: Rising incidence of IBD due to urbanization and dietary changes.
- India: Increased pharmaceutical investments in biosimilars for cost-effective treatment options.
Rest of the World (ROW)
- Emerging markets witnessing growth in online pharmaceutical sales.

Market Dynamics

Drivers

Rising Incidence of IBD: Sedentary lifestyles, poor diets, and genetic predisposition contribute to increasing cases worldwide.
Advancements in Biologic Therapies: The introduction of targeted biologics and JAK inhibitors has improved treatment outcomes.
Expansion of Online Pharmacies: Digital pharmacies are enhancing accessibility, particularly in cost-sensitive regions.

Trends

Innovative Product Launches:
- Lilly’s Mirikizumab (April 2023): Approved for Crohn’s disease, enhancing the treatment pipeline.
- Pfizer’s Xeljanz (August 2023): New oral JAK inhibitor variant for ulcerative colitis treatment.
Increased Research Investments: Companies like Cytoreason and Allergan are leveraging AI-driven drug discovery for novel IBD therapeutics.

Challenges

High Cost of Treatment:
- Ulcerative Colitis: Average treatment cost ranges from USD 6,000 to USD 12,000 annually.
- Crohn’s Disease: Treatment expenses can exceed USD 30,000 per year.
Reimbursement Barriers: Strict policies in several countries hinder patient access to premium biologic therapies.

Get more details by ordering the complete report